Background: Glycolysis is considered to be the root of cancer development and progression, which involved a multi-step enzymatic reaction. Our study aimed at figuring out which glycolysis enzyme participates in the development of colorectal cancer and its possible mechanisms. Methods: We firstly screened out Aldolase B (ALDOB) by performing qRT-PCR arrays of glycolysis-related genes in five paired liver metastasis and primary colorectal tissues, and further detected ALDOB protein with immunohistochemistry in tissue microarray (TMA) consisting of 229 samples from stage I-III colorectal cancer patients. CRISPR-Cas9 method was adopted to create knock out colon cancer cell lines (LoVo and SW480) of ALDOB. The effect of ALDOB on cell proliferation and metastasis was examined in vitro using colony formation assay as well as transwell migration and invasion assay, respectively. Results: In TMA, there was 64.6% of samples demonstrated strong intensity of ALDOB. High ALDOB expression were associated with poor overall survival and disease-free survival in both univariate and multivariate regression analyses (P<0.05). In vitro functional studies of CCK-8 demonstrated that silencing ALDOB expression significantly (P<0.05) inhibited proliferation, migration and invasion of colon cancer cells. Mechanically, silencing ALDOB activated epithelial markers and repressed mesenchymal markers, indicating inactivation of ALDOB may lead to inhibition of epithelial-mesenchymal transition (EMT). Conclusion: Upregulation of ALDOB promotes colorectal cancer metastasis by facilitating EMT and acts as a potential prognostic factor and therapeutic target in colorectal cancer.
Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer deaths in the US [1] . In China, the incidence of CRC has been increasing in recent years as living conditions improve and eating habits change. Surgical resection remains the only curative treatment option for CRC [2] . However, a considerable proportion of CRC patients develop recurrence or metastasis within 5 years after surgical treatment. Thus, a better understanding of the underlying mechanisms that promote the pathogenesis of CRC is urgently needed.
Unlike many differentiated cells in an adult organism, tumor cells have an unrestricted capacity to divide and proliferate. Relentless biosynthesis of macromolecules that are needed for the growth of newly divided cells requires the uptake of glucose and other carbon sources in excess of energetic needs [3, 4] . The vast majority of tumor cell types display modified rates and pathways of energetic and anabolic metabolism in comparison to their tissue of origin [5] . The Warburg effect, also known as aerobic glycolysis, is a shift from oxidative phosphorylation to glycolysis, a feature of which is increased lactate production even at normal oxygen concentrations, and is considered to be the root of cancer development and progression [6, 7] .
In the present study, we performed qRT-PCR arrays of glycolysis-related genes in five paired liver metastasis tissues and primary colorectal tissues. Aldolase B (ALDOB) was found mostly overexpressed in metastasis tissues and chosen for further research. Thus, we then focused on investigation of ALDOB expression in CRC tissues and its clinical significance and biological function in colon cancer cells, and we also explored the underlining mechanisms regulated by ALDOB in colon cancer cells.
Material and Methods

Patients and samples
To detect the clinical importance of ALDOB expression in cases with CRC, a tissue microarray (TMA) consisted of 229 patients with pathologically and clinically confirmed CRC was used for IHC study, including 19 cases at stage I, 68 at stage II, 106 at stage III, and 36 at stage IV. All patients included underwent primary tumor resection. The characteristics of the samples are shown in Table 1 . Construction of the TMA was performed as described previously [8] .
RNA extraction, reverse transcription, and qRT-PCR analysis
Total RNA was isolated from five paired tissues from patients with synchronous liver metastases using TRIzol® reagent (15596-026, Invitrogen). A PrimeScript™ RT Master Mix (Perfect Real Time) kit (RR036A, Takara) was used to synthesize first-strand cDNA from total RNA. After that, SYBR Green realtime PCR assays were performed using ABI 7900HT (Applied Biosystems, USA). The expression level of RNA was normalized to the level of β-actin. The primers for qRT-PCR analysis were synthesized by Huagene (Shanghai, PRC), the sequences of which are shown in Table 1 .
Immunohistochemical staining staining
Immunohistochemical staining (IHC) staining was performed as described previously [8] . Commercial monoclonal antibodies to ALDOB (titer 1:100, ab133333, Abcam), which has weak cross react with ALDOC (according to data provided by the manufacturer), was used and PBS was used as a negative control. No positive control has been done due to lack of liver tissue sections. Evaluation of the result was performed according the criteria as recommended by the manufacturer. The staining intensity was scored as 0 (negative), 1 (weak), 2 (medium) or 3 (strong). Extent of staining was scored as 0 (<5%), 1(5-25%), 2 (26-50%), 3 (51-75%) and 4 (>75%) according to the percentages of the positive staining areas in relation to the whole carcinoma area. Scores for staining intensity and percentage of positive cells were then multiplied to generate the immunoreactivity score (IRS) for each case. Samples having a final staining score of ≤ 4 were considered to be low and those with score of > 4 were considered to be high.
CRISPR/CAS9 knockout
Colon cancer cells (LoVo, SW480) were transfected with lentiCas9-Blast (Addgene #52962) virus and selected by blasticidin for 5 days. The stable blasticidin resistant sub-lines were then infected with ALDOB specific lenti-gRNA-puro (Addgene #52963) lentivirus. The guide sequence was preselected from three different guideRNA pairs using in silico on-and off-target predictions (http:// crispr.mit.edu/). The sgRNA target sequences for ALDOB were 5'-ATTACCTCTGGTTCAACAAT-3' (sgRNA 1#), 5'-AATATCCTTACCTTGAATGG-3' (sgRNA 2#). The sgRNA sequence targeting firefly GFP was used as control, which was 5'-GCACTACCAGAGCTAACTCA-3'. Stably transfected cells were isolated using puromycin selection after the cells were transfected with expression vector or control plasmids. The knockout effect was tested by western blot of proteins extracted in a population of knockout LoVo and SW480 cells.
Western blot
Briefly, equal quantities of cellular proteins were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membranes, and immunoblotted with primary antibody for detection of ALDOB(titer 1:1,000, ab133333, Abcam), E-cadherin (titer 1/1,000 dilution; Abcam), N-cadherin (titer 1/10,000 dilution; Abcam), and Vimentin (titer 1/1,000 dilution; Abcam) overnight at 4°C. After incubation with a secondary antibody, blots were visualized using ECL (Pierce, Thermo Scientific, USA) and detected using a BioImaging Table 1 Primers sequences used in the text System. Relative protein expression was normalized to β-actin.
CCK8 assay
Cells transfected with ALDOB-sgRNA or GFP-sgRNA lentivirus were plated in 96-well plates at density of 2×10 3 cells/well and cultured for 24, 48, 72 or 96 h, respectively. 10 μL of CCK8 solution (Dojindo Laboratories, Kumamoto, Japan) was added to each well, incubated for 2h at 37°C and read at 450nm. All experiments were performed 3 times.
Colony formation assay
Cells infected with ALDOB-sgRNA lentivirus or GFP-sgRNA lentivirus was seeded in 6-well plates at a density of 400 per well and cultured at 37°C for 14 days. Cells were washed twice with PBS, fixed with 4% paraformaldehyde, stained with Giemsa for 10 minutes and washed 3 times with double distilled H 2 O. The colonies containing more than 50 cells were counted using light microscopy. Colony-forming efficiency (CFE %) was defined as the ratio of the number of colonies formed in culture to the number of cells inoculated.
In vitro cell migration and invasion assays
The migration and invasion assays were conducted in a 24-well Transwell chamber (Costar, Cambridge, MA) with uncoated membranes or membranes coated with Matrigel (BD Biosciences, San Jose, CA, USA). Cells (4×10 4 per well) were resuspended in serum-free medium and seeded into the upper chamber. Culture medium containing 10% fetal bovine serum was added to the lower chamber as the chemoattractant. The cells were incubated in a humidified incubator at 37°C for 48 hours (migration assays) or 72 hours (invasion assays). Non-invading cells in the upper chambers were removed with cotton swabs. The cells attached to the lower surface were fixed and stained with crystal violet. The number of cells which were attached to the lower surface was counted in five random fields under a microscope (×200).
Ethic statement
This study was approved by the Shanghai Cancer Center Research Ethics Committee. The methods were carried out in accordance with the approved guidelines. Informed consent was obtained from each patient according to the committee's regulations.
Statistical Analysis
The statistical associations between clinical parameters and IHC staining were tested by χ 2 test to compare the expected frequencies and the observed frequencies in two groups. The 5-year overall survival (OS) and disease-free survival (DFS) were calculated by the Kaplan-Meier method to estimate the survival and hazard functions of censored data. The difference in survival between the groups at each observed event time was compared by the log rank test. Variables that seemed to be significantly associated with survival in univariate analysis were included into multivariate analysis, which was performed with Cox proportional hazard model to relate survival to a collection of other risk factors. A P value of <0.05 was considered statistically significant. All statistical analyses were carried out by SPSS for Windows, version 21.0 (SPSS, Chicago, IL).
Results
Glycolytic enzymes ALDOB might promote tumor metastasis in colorectal cancer
Glycolysis is a multi-step enzymatic reaction involving with a series of rate-limiting enzymes (Fig.1A) . Recent studies have provided evidence that some glycolytic enzymes are more complicated, multifaceted proteins rather than simple components of the glycolytic pathway [9] . In order to find the potential enzymes that may be involved in cancer metastasis, qRT-PCR assay was used to measure the levels of glycolytic enzyme mRNA expression in five paired tissues from patients with synchronous liver metastasis, who all underwent synchronous primary tumor and liver metastases resection. We found that the expression of ALDOB changed most significantly in liver metastases compared with corresponding primary tumors (Fig.1B) . Heatmap of differentially expressed genes in five paired primary colorectal cancer tissues and liver metastases using qRT-PCR and the results were normalized by Z-score. Each column represents a specimen which is denoted on the above and each role represents a gene which is denoted on the right. Red color indicates genes that were upregulated and green color indicates genes that were downregulated. P: primary colorectal cancer tissue; M: corresponding liver metastasis. Li Fig. 2A-D .
According to IRS of each patients, 64.6% (148/229) of patients were assigned to the ALDOB-high group and 35.4% (81/229) of patients to the ALDOB-low group. The correlation of ALDOB in CRC with clinical features is provided in Table 2 . The positive expression of ALDOB was noted more often in patients with more advanced tumor stage (P<0.05).
At last follow-up, 71 patients died and 87 patients experienced tumor recurrence. The OS rates at 3 and 5 The Kaplan-Meier plot demonstrated that high expression of ALDOB was associated with both poor OS and DFS (Fig. 2E, 2F) . Besides, in univariate Cox proportional hazard analysis, high CEA level, advanced tumor stage, presence of lymphovascular invasion and perineural invasion were significantly associated with poor prognosis in terms of OS (P<0.05, 
Altered expression of ALDOB affected migratory and invasive ability of colon cancer cells in vitro
The above results demonstrate that overexpressed ALDOB is correlated with tumor progression and poor survival of colorectal cancer. Thus, we want to explore whether knockdown of ALDOB can inhibit growth of colon cancer cells. Two sgRNAs were designed Table 3 . Univariate and multivariate survival analyses of ALDOB expression and overall survival for patients with colorectal cancer Table 4 Univariate and multivariate survival analyses of ALDOB expression and disease free survival for patients with colorectal cancer against ALDOB and transfected into two colon cancer cell lines LoVo and SW480, which have high endogenous ALDOB expression (Fig. 3A) . Western blot verified that ALDOB protein was inactivated in both LoVo and SW480 cells transfected with the two sgRNAs (Fig. 3B) . Cell proliferation assay and colony formation assays showed that proliferation and colony formation abilities of both LoVo and SW480 cells transfected with sgRNA-1 or -2 was remarkably inhibited compared with that of those transfected with control sgRNA (Fig. 3C and  3D ), indicating that ALDOB inactivation suppressed cell growth. Transwell migration assay and Matrigel invasion assay showed that silencing ALDOB expression inhibited migration and invasion of LoVo and SW480 cells with statistically significant difference ( Fig. 3E and  3F ) (P<0.05).These findings suggest that knockdown of ALDOB represses proliferation and invasion ability of colorectal cancer cells.
ALDOB promotes epithelial-mesenchymal transition in human colorectal cancer
Studies demonstrate that cancer cells may have epithelial-mesenchymal transition (EMT) before metastasis, by which cancer cells lose cell-cell adhesion, apical-basolateral polarity and epithelial markers, and acquire motility, spindle-cell shape and mesenchymal markers [10] . Thus EMT is thought to facilitate cancer cell motility, invasion and metastasis. Based on this knowledge and our results above, we hypothesize that ALDOB can induce EMT during its promotion of migration and invasion. To this end, we explored the markers of EMT with Western blot: E-cadherin (epithelial marker), N-cadherin and vimentin (mesenchymal markers). The result showed that silencing ALDOB activated epithelial markers and repressed mesenchymal markers (Fig. 4) , indicating inactivation of ALDOB may lead to inhibition of EMT, which needs to be verified by further research.
Discussion
Aberrant expression and activity of metabolic enzymes are the hallmarks of tumorigenesis and metastasis. Advances in understanding the mechanisms of tumor progression and metastasis have clearly highlighted the importance of the tumor metabolism alteration, which supports not only tumor cells' energy requirements but also their enormous biosynthetic needs. Such metabolic alterations modulate glucose, amino acid, fatty acid-dependent metabolite biosynthesis and energy production [5, 11] . In the 1920s, Warburg made the striking discovery that in contrast to that normal cells produce ATP mainly via mitochondrial oxidative phosphorylation, cancer cells prefer to metabolize glucose via glycolysis, even in the presence of ample oxygen [6] . In the present study, we firstly screened out ALDOB by performing qRT-PCR arrays of glycolysis-related genes in five paired liver metastasis tissues and primary colorectal tissues. We further explored by IHC of TMA and found that the expression levels of glycolytic enzymes ALDOB was significantly higher in cancer tissues than their normal tissues. High ALDOB expression was correlated with advanced tumor stage, and ALDOB expression was an independent prognosis biomarker in CRC. Silencing ALDOB expression inhibited proliferation and invasion in colon cancer cells by inhibiting epithelial-mesenchymal transition (EMT).
It is currently well understood that the Warburg effect plays a critical role in the carcinogenesis and development of cancer. A recent publication has shown that genes involved in aerobic glycolysis are over-expressed in at least 24 different types of cancer corresponding to approximately 70% of all cancers [12] . Studies have provided evidence that some glycolytic enzymes are more complicated, multifaceted proteins rather than simple components of the glycolytic pathway [9] . These glycolytic enzymes have acquired additional non-glycolytic functions in many aspects. For example, pyruvate kinase M2 (PKM2) facilitates colon cancer cell migration and drug resistance via the modulation of STAT3 signal [13, 14] . Alpha-enolase (ENO1) promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway [15] , and ENO1 is confirmed as a novel substrate of FBXW7 in colorectal cancer [16] . Lactate dehydrogenase A (LDHA) acts as oncogenic role in prostate cancer [17] . Aldolase A (ALDOA) may provide good survival prediction for stage I-IV colorectal cancer patients [18] . GLUT-4 may be up-regulated by p38- MAPK signaling to enhance glycolysis in gastric cancer cells [19] .
ALDOB, also known as fructose-bisphosphate aldolase, is an important enzyme for glucose and fructose metabolism. It is found primarily in the liver, but it is also present at lower levels in kidney and intestinal cells [20, 21] . It cleaves fructose1-phosphate to yield glyceraldehyde and dihydroxyacetone phosphate. Accumulation of fructose 1-phosphate in tissues due to a defect in ALDOB may result in hereditary fructose intolerance [22] . Although the role of aldolase in metabolism is well established, there is growing evidence for many alternative functions of this enzyme. In particular, aldolase interacts with various proteins unrelated to glycolytic enzymes, including F-actin [23] , ARNO [24] , tubulin [25] and is crucial for proliferation [26] and invasion [27] of cancer cells through a non-glycolytic pathway. In the present study, ALDOB was highly expressed in CRC and its expression was correlated with tumor stage. Thus, the expression of ALDOB can be valued as a prognostic biomarker in CRC.
As EMT is one of the key events in tumor invasion and metastasis, and ALDOB expression was correlated with advanced tumor stage, and silencing ALDOB expression inhibited colon cancer cells proliferation and invasion abilities. We then tested whether ALDOB performed its functions on cancer cell by way of inducing EMT pathway. As anticipated, silencing of ALDOB expression led to increased protein levels of epithelial marker (E-cadherin) and decreased expression of mesenchymal marker (N-cadherin, vimentin), suggesting that silencing of ALDOB might lead to a reversion of EMT progression in CRC.
Although the clinical significance of ALDOB in CRC has been revealed, several limitations of this study need further discussion. Firstly, the number of patients enrolled in this study was small, especially for the patients at stage I and stage IV. Secondly, an independent external cohort is necessary to validate our findings. Thirdly, more detailed studies should be conducted to uncover the biological mechanisms of ALDOB in CRC.
In summary, the present study confirmed that ALDOB plays a critical role in CRC by regulating EMT pathway in tumor progression and metastasis and high expression of ALDOB was an independent adverse prognostic factor for both OS and DFS in CRC patients. ALDOB may serves as a new biomarker and potential therapeutic target for CRC treatment.
